How This Actually Works, Step by Step

The sequence below is the one our team runs most often for neurodegenerative conditions. It is designed to avoid the single biggest mistake families make: flying to China before anyone has looked at the records.

Step one — you send the file. Existing examination reports go to us: EMG/NCS results, MRI images and reports, bloodwork, genetic panels if done, and a short summary of symptom onset and progression. If a diagnosis is already established, the diagnostic letter matters as much as the test results.

Step two — translation and case preparation. Records in English, Arabic, Russian, or Spanish are translated into a structured Chinese medical summary. Neurology departments here read cases in a specific format, and a well-organized file shortens review time considerably.

Step three — specialty review. The relevant neurology team reviews the file and returns a written second opinion: their read on the diagnosis, what additional testing they would want, and whether an in-person visit would change management. This is a written second opinion, not a prescription, and it typically takes several business days.

Step four — video consultation, if useful. For motor neuron disease, where history-taking matters enormously, a live conversation with the specialty team often adds more than another scan. You describe symptoms and goals; they explain what they can and cannot offer.

Step five — decide whether to travel. Sometimes the answer is that the workup can be completed at home and only a specific intervention warrants the trip. Sometimes the answer is that a fuller evaluation in China makes sense. Either way, you decide with information rather than hope.

Step six — arrival and coordination. If you come, we handle registration, hospital medical card creation, appointment scheduling through the hospital’s international office, bilingual accompaniment, and communication with the clinical team. Admission itself always remains subject to hospital rules.

Which Hospitals Carry Weight in Neurology

China has more than 35,000 hospitals. Our database covers 340+ top-ranked institutions across 37 cities, filtered by Fudan rankings and JCI accreditation — roughly the top 5% of the country’s hospital system.

For neurology specifically, three names come up repeatedly in the Fudan specialty reputation rankings: Peking Union Medical College Hospital in Beijing, Huashan Hospital in Shanghai, and West China Hospital in Chengdu. These are large institutions. Huashan’s neurology department handles one of the highest volumes of neuromuscular cases in the country, which matters for a condition where diagnostic accuracy depends on how many similar cases a team has seen.

Beijing hosts 21 of the Fudan Top 100 hospitals; Shanghai has 18; Guangzhou 10. If you are searching for the best hospitals for ALS treatment in China, the practical shortlist usually starts with those three cities. You can browse the full breakdown by city and specialty on our ranked hospital directory, and the neurology-specific rankings on our department pages.

One honest caveat: “best” is not a single axis. A hospital with a famous name may have a three-week wait for a specialist outpatient slot. A slightly lower-ranked institution in the same city may see you in five days. For a progressive condition, time often outweighs prestige.

A Realistic Timeline

Families consistently underestimate two things: document translation and appointment lead time. Here is what the calendar actually looks like.

Total elapsed time from first contact to sitting in a consultation room: typically four to eight weeks. Anyone promising faster is either working with an unusual case or overpromising.

That timeline answers a related question families ask — how long does ALS treatment take in China. There is no single answer, because motor neuron disease care is not a fixed course of treatment. It is ongoing management: medication adjustment, symptom control, respiratory monitoring, nutritional support, and rehabilitation. A first evaluation visit usually spans one to two weeks. Longer stays depend on what the clinical team finds and what you decide together.

What Can Go Wrong — and What Happens Then

Three failure modes come up again and again. None of them are catastrophic, but all of them cost time.

The records are incomplete. A diagnosis without EMG tracings, or an MRI report without the images themselves, forces the Chinese team to repeat testing. That adds days and money. The fix is simple: send raw data, not just conclusions.

The expectation mismatch. Some families arrive expecting a treatment protocol that does not exist anywhere in the world. Motor neuron disease has no cure, and no hospital in China claims otherwise. What top departments offer is meticulous diagnostic confirmation, access to approved therapies, enrollment discussions for clinical trials where eligible, and aggressive symptom management. If a provider promises reversal, walk away.

The appointment does not materialize. Public hospital outpatient registration in China generally cannot be pre-booked from overseas — same-day queuing is the norm for standard channels. International departments and VIP channels can be coordinated in advance, at roughly 1.5 to 2 times the standard fee. When we coordinate an appointment and cannot secure it, the coordination fee is refunded in full.

Stem Cell Claims: What the Evidence Actually Says

This is the question that brings many families to China in the first place, so it deserves a direct answer. Is stem cell therapy for motor neuron disease safe in China? Safety and efficacy are separate questions, and conflating them is where people get hurt.

China has a substantial research presence in regenerative neurology, and several academic centers run registered clinical trials. Participation in a properly registered trial, with ethics committee oversight and informed consent, is a defined pathway with defined risks. That is different from commercial “stem cell clinics” that advertise direct-to-patient injections for a fee.

The international scientific consensus, reflected in guidance from neurological societies, is that stem cell therapy is not an established treatment for motor neuron disease. No regulatory agency has approved it for this indication. Families who pursue unregulated injections frequently pay tens of thousands of dollars and return home with no measurable benefit and occasionally with complications.

Our position is straightforward: we will help you understand what is available at academic institutions, and we will not facilitate unproven commercial injections. If a clinic cannot show you a trial registration number and an ethics approval, that tells you what you need to know.

Practical Considerations: Records, Visas, and Money

Frequently Asked Questions